Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Opening Session Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement

Jan

02

Today In Oncology

ASTRO Relaunches Research Foundation Under a Single, Focused Identity

Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma

A Novel Paradigm in Acute Kidney Injury Congestive Nephropathy in RCC With IVC Thrombus

County-Level Obesity Prevalence May Predict Obesity-Related Cancer Rates in Young Adults

Advertisement

© 2026 HSP News Service, L.L.C.